|
|
|
| Construction and Evaluation of the Tumor Cell Model with Stable Expression of HPV16 and 18 Subtypes Antigen E7 |
| JIANG Xin, HU Lai-Yin, SONG Ya-Wen, SUN Jing, SONG Hou-Hui, XIA Jing*, CHENG Chang-Yong* |
| College of Animal Science and Technology & College of Veterinary Medicine/Key Laboratory of Applied Technology on Green -Eco-Healthy Animal Husbandry of Zhejiang Province/Zhejiang Provincial Research Center for Animal Health Diagnostics ＆ Advanced Technology/Zhejiang International Science and Technology Cooperation Base for Veterinary Medicine and Health Management/China-Australia Joint Laboratory for Animal Health Big Data Analytics, Zhejiang A&F University, Hangzhou 311300, China |
|
|
|
|
Abstract Human papillomavirus (HPV) is a common genital tract virus HPV subtypes 16 and 18 have a close relationship with cervical cancer. Currently, there are 6 types of preventive HPV vaccines available worldwide. However, these vaccines are only for preventive and cannot be used for the treatment of infected cases. Therefore, this study constructed the TC-1-HPV18 E7 cell model co-expression HPV16 E7 and HPV18 E7 using mouse (Mus musculus) cervical cancer cell line TC-1 as a base model. The attenuated Listeria monocytogenes (LM) was used as a vector for the recombinant strain vaccine LM-HPV18 E7 to deliver tumor antigens, and the therapeutic efficacy of the recombinant strains in the TC-1-HPV18 E7 tumor-bearing mouse model was evaluated. The results showed that the TC-1-HPV18 E7 cell model and mouse model were successfully constructed. There was no difference in tumor formation between TC-1-HPV18 E7 tumor-bearing mice and TC-1 tumor-bearing mice, indicating that stable expression of exogenous genes had no impact on the cell and mouse models. LM-HPV18 E7 vaccine exhibited significant therapeutic effects on tumors in TC-1-HPV18 E7 tumor-bearing mice compared with TC-1 tumor-bearing mice, which proving that LM was a potent live vaccine vector platform. This study expands the use of TC-1-based cell models and provides a reference for the research of LM as a therapeutic vaccine vector.
|
|
Received: 10 January 2024
|
|
|
|
Corresponding Authors:
* Lamge@zafu.edu.cn; xiajing125@zafu.edu.cn
|
|
|
|
[1] 李莉莉, 王鹤蓉, 周芷亦, 等. 2016. TC-1-HPV16L1细胞模型与动物模型的建立与评价[J]. 北京工业大学学报, 42(10): 1581-1587.
(Li L L, Wang H R, Zhou Z Y, et al.2016. Establishment and evaluation of TC-1-HPV16L1 cell model and animal model[J]. Journal of Beijing University of Technology, 42(10): 1581-1587.)
[2] 刘晨, 宋亚雯, 蒋昕, 等. 2023. 结核分枝杆菌相关抗原在基于减毒单增李斯特菌为载体的宫颈癌免疫治疗中的增强效果[J]. 农业生物技术学报, 31(11): 2367-2376.
(Liu C, Song Y W, Jiang X, et al.2023. Enhanced effect of Mycobacterium tuberculosis-related antigens in cervical cancer immunotherapy based on attenuated Listeria monocytogenes[J]. Journal of Agricultural Biotechnology, 31(11): 2367-2376.)
[3] 赵雪莲, 赵方辉. 2023. 2022年世界卫生组织HPV疫苗立场文件的解读[J]. 中国预防医学杂志, 24(03): 161-167.
(Zhao X L, Zhao F H.2023. Interpretation of “Human papillomavirus vaccines: WHO position paper, December 2022”[J]. Chinese Journal of Preventive Medicine, 24(03): 161-167.)
[4] Baldwin P J, van der Burg S H, Boswell C M, et al.2003. Vaccinia-expressed Human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia[J]. Clinical Cancer Research, 9(14): 5205-5213.
[5] Basu P, Mehta A, Jain M, et al.2018. A randomized phase 2 study of ADXS11-001 listeriolysin O immunotherapy with or without cisplatin in treatment of advanced cervical cancer[J]. International Journal of Gynecological Cancer, 28(4): 764-772.
[6] D'Orazio S E F.2019. Innate and adaptive immune responses during Listeria monocytogenes infection[J]. Microbiology Spectrum, 7(3): 1-40.
[7] Dai C, Zhang Q, Shen L, et al.2022. Quercetin attenuates quinocetone-induced cell apoptosis in vitro by activating the P38/Nrf2/HO-1 pathway and inhibiting the ROS/Mitochondrial apoptotic pathway[J]. Antioxidants (Basel), 11(8): 1498.
[8] Davidson E J, Boswell C M, Sehr P, et al.2003. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding Human papillomavirus 16/18 oncoproteins[J]. Cancer Research, 63(18): 6032-6041.
[9] de Martel C, Georges D, Bray F, et al.2020. Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis[J]. The Lancet Global Health, 8(2): E180-E190.
[10] Ding Y D, Shu L Z, He R S, et al.2023. Listeria monocytogenes: A promising vector for tumor immunotherapy[J]. Frontiers in Immunology, 14: 1278011.
[11] Doorbar J, Quint W, Banks L, et al.2012. The biology and life-cycle of Human papillomaviruses[J]. Vaccine, 30: F55-F70.
[12] Drake C G, Pachynski R K, Subudhi S K, et al.2022. Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double deleted based immunotherapy, in metastatic castration-resistant prostate cancer[J]. Prostate Cancer and Prostatic Diseases, 25(2): 219-228.
[13] Fiander A N, Tristram A J, Davidson E J, et al.2006. Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: Clinical results from a multicenter phase Ⅱ trial[J]. International Journal of Gynecological Cancer, 16(3): 1075-1081.
[14] Galicia-Carmona T, Arango-Bravo E, Serrano-Olvera J A, et al.2021. ADXS11-001 LM-LLO as specific immunotherapy in cervical cancer[J]. Human Vaccines & Immunotherapeutics, 17(8): 2617-2625.
[15] Howell L M, Forbes N S.2022. Bacteria-based immune therapies for cancer treatment[J]. Seminars in Cancer Biology, 86: 1163-1178.
[16] Kaufmann A M, Stern P L, Rankin E M, et al.2002. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified Human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer[J]. Clinical Cancer Research, 8(12): 3676-3685.
[17] Lin K Y, Guarnieri F G, Staveley-O'Carroll K F, et al.1996. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen[J]. Cancer Research, 56(1): 21-26.
[18] Muhr L S A, Eklund C, Lagheden C, et al.2022. Improving Human papillomavirus (HPV) testing in the cervical cancer elimination era: The 2021 HPV LabNet international proficiency study[J]. Journal of Clinical Virology, 154: 105237.
[19] Oladejo M, Paterson Y, Wood L M.2021. Clinical experience and recent advances in the development of based tumor immunotherapies[J]. Frontiers in Immunology, 12: 1-18.
[20] Peng S, Ferrall L, Gaillard S, et al.2021. Development of DNA vaccine targeting E6 and E7 proteins of Human papillomavirus 16 (HPV16) and HPV18 for immunotherapy in combination with recombinant vaccinia boost and PD-1 Antibody[J]. mBio, 12(1): e03224-20.
[21] Serrano B, de Sanjosé S, Tous S, et al.2015. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions[J]. European Journal of Cancer, 51(13): 1732-1741.
[22] Sun J, Wang J, Jiang X, et al.2024. LADS: A powerful vaccine platform for cancer immunotherapy and prevention[J]. BMC Biology, 22(1): 291.
[23] Tommasino M.2017. The biology of beta Human papillomaviruses[J]. Virus Research, 231: 128-138.
[24] Wood L M, Paterson Y.2014. Attenuated Listeria monocytogenes: A powerful and versatile vector for the future of tumor immunotherapy[J]. Frontiers in Cellular and Infection Microbiology, 4: 1-22.
[25] Yang A, Farmer E, Wu T C, et al.2016. Perspectives for therapeutic HPV vaccine development[J]. Journal of Biomedical Science, 23(1): 75.
[26] Yang A, Farmer E, Lin J, et al.2017. The current state of therapeutic and T cell-based vaccines against Human papillomaviruses[J]. Virus Research, 231: 148-165.
[27] Zhu B, Liu Y, Zuo T, et al.2019. The prevalence, trends, and geographical distribution of Human papillomavirus infection in China: The pooled analysis of 1.7 million women[J]. Cancer Medicine, 8(11): 5373-5385. |
|
|
|
